Detalles de la búsqueda
1.
In Vitro Activity of Ceftibuten-Avibactam against ß-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.
Antimicrob Agents Chemother
; 67(1): e0134622, 2023 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36602322
2.
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 µg/mL), a Novel ß-Lactam/ß-Lactamase Inhibitor Combination.
J Clin Microbiol
; 61(7): e0165722, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395644
3.
The primary pharmacology of ceftazidime/avibactam: resistance in vitro.
J Antimicrob Chemother
; 78(3): 569-585, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702744
4.
The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
J Antimicrob Chemother
; 78(4): 871-892, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36883356
5.
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by ß-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
J Antimicrob Chemother
; 78(11): 2672-2682, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700689
6.
The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.
J Antimicrob Chemother
; 77(9): 2321-2340, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665807
7.
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
J Antimicrob Chemother
; 77(9): 2341-2352, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35660869
8.
Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012-2018.
Ann Clin Microbiol Antimicrob
; 21(1): 13, 2022 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313912
9.
Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.
Antimicrob Agents Chemother
; 65(7): e0200020, 2021 06 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33972241
10.
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32071051
11.
In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017.
J Antimicrob Chemother
; 75(7): 1859-1873, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32277820
12.
In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).
J Antimicrob Chemother
; 75(2): 384-391, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31742604
13.
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.
J Antimicrob Chemother
; 75(5): 1165-1173, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32040168
14.
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ann Clin Microbiol Antimicrob
; 19(1): 14, 2020 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32238155
15.
Characterization of ß-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against ß-Lactamase Producers.
Antimicrob Agents Chemother
; 63(6)2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30910899
16.
In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30670424
17.
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30670413
18.
Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
J Antimicrob Chemother
; 74(2): 425-431, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30380060
19.
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.
Antimicrob Agents Chemother
; 62(7)2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29686147
20.
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
Antimicrob Agents Chemother
; 62(7)2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29735568